Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 2nd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 2nd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

October 15th 2019

MBC Treatment Not Aligned With NCCN Guidelines Leads to Higher Patient Cost Responsibility

Allison Inserro

Patients on Medicare with metastatic breast cancer who receive treatment that is discordant with NCCN guidelines bear a greater burden of patient cost responsibility than patients who do receive care according to treatment guidelines.

October 14th 2019

Erich Mounce: Partnerships and Performance Data Can Initiate Sustainable Growth in Clinical Practice

Initiating sustainable growth in clinical practices can be difficult, but through economies of scale derived from partnerships and performance data collection, optimal care can be administered efficiently, said Erich Mounce, chief operating officer, OneOncology.

October 13th 2019

Dr Amila Patel: How Flatiron's Clinical Workflow Efforts Will Expand Beyond EHRs

Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health, discusses how Flatiron is working to implement clinical workflow features that expand beyond the electronic health record (EHR).

October 11th 2019

Trends in Oncology Dr Michael Kolodziej Expects to See in Coming Years

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc., outlines the trends he expects to see in the coming years that will impact oncology.

October 8th 2019

Dr James Hamrick: There's Been Progress in Patient-Centered Care, Albeit Slow

The healthcare system has gotten better at placing more of a priority on patient-centered care, but the progress has been slow, said James Hamrick, MD, senior medical director at Flatiron Health.

October 7th 2019

Nobel Prize Honors 3 Who Showed How Cells Adapt to Oxygen Levels

Mary Caffrey

The mechanism studied affects a broad range of physiological responses and is now the focus of intense study by the pharmaceutical industry.

October 6th 2019

Dr Lawrence Shulman Discusses the Role of Rising Drug Costs in Value-Based Care

Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania, explains how providers are reacting to more effective, more costly therapies entering the cancer landscape.

October 5th 2019

Nina Chavez on How CAR T, Other Expensive Therapies Create Reimbursement Challenges

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.

October 2nd 2019

Implementing Practice Transformation, Integrating Primary Care to Provide High-Quality Cancer Care

Jaime Rosenberg

As practices work to provide the best care for their patients while also containing costs, it has become clear that the old ways of doing things won’t cut it.

September 30th 2019

Nina Chavez: OCM Has Made Community Oncologists Better Business People

The Oncology Care Model (OCM) over the last couple of years has helped us to look at things that we didn’t really think of from an oncology perspective, explained Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd.

September 29th 2019

Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

September 27th 2019

Defining, Standardizing, and Acting on Patient-Reported Outcomes in Cancer Care

Jaime Rosenberg

During a panel discussion on defining, standardizing, and reporting quality in cancer care during the National Comprehensive Cancer Network Policy Summit held September 12 in Washington, DC, it became clear that stakeholders of all backgrounds have set their focus on one type of metric in particular: patient-reported outcomes.

September 27th 2019

Facilitating the Qualitative Improvement of Oncology Through Value-Based Care

Matthew Gavidia

Coverage of the first half of the Institute for Value-Based Medicine® (IVBM®) session held September 19, 2019, in Philadelphia, Pennsylvania. IVBM® is an initiative of The American Journal of Managed Care®.

September 22nd 2019

Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM

CMS is trying to make a 2-sided risk model in the Oncology Care Model enticing for practices, but there is still a lot of math practices need to work out before making the decision, said Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago.

September 21st 2019

Dr James Hamrick Discusses Bringing Value to Patients Through Engagement

The more engaged patients who have more access to their data and are more informed about what’s going on are actually going to have better outcomes most of the time, explained James Hamrick, MD, senior medical director at Flatiron Health.

September 20th 2019

Florida Cancer Specialists & Research Institute and Humana Sign Multiyear Agreement

Florida Cancer Specialists & Research Institute and Humana Inc. have signed a new multiyear agreement that provides Humana members with in-network access to FCS’ comprehensive range of oncology services.

September 18th 2019

Too Much, Too Fast: Providers Need More Time to Operationalize Medicare's New Radiation Oncology Model

Jessica Walradt

CMS' new radiation oncology payment model is slated to begin on January 1, 2020, but the significant billing changes that the model requires will require more time.

September 18th 2019

Lessons From the Field: How Practices Are Succeeding Under OCM

Jaime Rosenberg

As rising drug costs continue to take up a larger portion of the total cost of care, practices in the Oncology Care Model find themselves in control of a shrinking portion of total costs, according to anecdotes from an academic medical center and a community-based practice during the National Comprehensive Cancer Network’s Policy Summit held September 12 in Washington, DC.

September 15th 2019

Lani Alison Discusses How the OCM Allowed for Better Integration of Palliative Care

Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, explains how the implementation of the Oncology Care Model (OCM) allowed practices to better integrate palliative care.

September 10th 2019

Dr Iuliana Shapira Offers Examples of How Innovation Can Transform Cancer Care Delivery

Innovation that transform cancer care delivery have to be multi-level, explained Iuliana Shapira, MD, chief medical officer, Regional Cancer Care Associates.

September 7th 2019

Mike Fazio: Practices Are Happier With PP4 Results in the OCM

There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.

September 5th 2019

Lani Alison Outlines Questions Patients Have About Care Pathways, Treatment Guidelines

Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, explains the questions that patients have about oncology care pathways and treatment guidelines.

September 1st 2019

Dr Shalom Kalnicki Discusses Bringing Value-Based Care to Radiation Oncology

The cost of radiation oncology services has typically been a small part of the Medicare and Medicaid budget, but with more patients having complex radiation treatments, it is becoming more important to have alternative payment models in the space, said Shalom Kalnicki, MD, FASTRO, FACRO, professor and chairman, radiation oncology, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine.

August 31st 2019

Incidences and Burden of Childhood Cancer Continue to Increase

Alison Rodriguez

Unlike cancers common in adults, childhood cancers are unlikely to be prevented by screening.

August 28th 2019

Dr Iuliana Shapira on Managing High Costs of Immuno-Oncology Drugs in Value-Based Care

Iuliana Shapira, MD, chief medical officer, Regional Cancer Care Associates (RCCA), discusses how RCCA is managing the higher costs of immuno-oncology drugs in value-based care.

August 26th 2019

Childhood Cancer Survivors Have a Heightened Risk of Heart Disease, Study Shows

Matthew Gavidia

Cancer treatment raises the risk of heart disease in childhood cancer survivors, as does diabetes and hypertension.

August 25th 2019

Dr Ginah Nightingale: Challenges of Treating Seniors With Cancer With Combination Therapies

When seniors with cancer are being treated with combination therapies, providers need to keep in mind more than just the complex regimens they’re administering, said Ginah Nightingale, PharmD, associate professor of pharmacy practice at Jefferson College of Pharmacy.

August 23rd 2019

Phase 1 Pancreatic Cancer Trial Identifies Effective Combination Treatment

Alison Rodriguez

Finding a cure for pancreatic cancer, which is among the deadliest cancers, will require both systemic therapy and local therapy, researchers said.

August 21st 2019

Research Reveals a Lack of Racial Diversity in Clinical Trials for Cancer Drugs

Matthew Gavidia

A new study shows a lack of racial and ethnic diversity in clinical trials for cancer drugs, highlighting issues currently being addressed by the FDA.

August 18th 2019

Lani Alison: How Providers Discuss the OCM With Patients

Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, discusses how providers discuss the Oncology Care Model (OCM) with patients and the questions they ask about it.

...

23 24 25 26 27 28 29 30 31

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions